Compugen to Present at SITC 2025

Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN), a clinical-stage cancer immunotherapy enterprise based in Israel, is set to present groundbreaking findings at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) scheduled from November 7 to 9, 2025, in National Harbor, Maryland. The company will unveil data from its first-in-human clinical trial assessing COM503 (GS-0321), an innovative anti-IL18BP antibody aimed at treating advanced solid malignancies.

Dr. Manish Sharma, Co-Director of Clinical Research at START Midwest, will present the research, identified under Abstract number 589, on November 7. This trial marks a significant milestone in the exploration of novel cancer immunotherapies targeting the IL-18 binding protein (IL18BP), which plays a critical role in immune regulation and tumor progression.

Compugen specializes in developing new therapeutic options utilizing its predictive computational discovery platform, Unigen™, powered by artificial intelligence and machine learning. With two proprietary candidates—COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT—both in Phase 1 development, Compugen is at the forefront of immuno-oncology innovation. Additionally, the company has a collaboration with AstraZeneca for Rilvegostomig, a PD-1/TIGIT bispecific antibody, which is advanced to Phase 3 trials.

Moreover, the company continues to build its therapeutic pipeline with early-stage immuno-oncology programs aimed at identifying novel mechanisms to mobilize the immune system against cancer. Through its commitment to innovation in cancer treatment, Compugen is poised to make substantial contributions to the field and enhance treatment options for patients grappling with advanced malignancies. For more information, the company can be contacted at ir@cgen.com.

Compugen Ltd. (Nasdaq: CGEN) is poised to capture investor attention with its upcoming presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 7, 2025. The company will share key findings from its first-in-human clinical trial for COM503 (GS-0321), an innovative anti-IL18BP antibody targeting advanced solid malignancies. This presentation could significantly impact investor sentiment and the stock’s trajectory.

As Compugen continues to leverage its predictive AI/ML platform (Unigen™) to develop cancer therapeutics, the success of COM503, alongside its other promising candidates like COM701 and COM902, could enhance the company's valuation. The anticipated results from the COM503 trial may validate the utility of Compugen’s proprietary technology and its potential in the immuno-oncology space.

Investors should consider the transformation in the landscape of cancer treatments, where precision and individualized therapies are becoming increasingly valuable. Compugen's focus on novel pathways, combined with its licensing agreements with larger partners like Gilead and AstraZeneca, illustrates a strong collaborative framework that may provide additional liquidity and funding for further advancements.

Given the market's current volatility and heightened interest in biotech innovations, maintaining a position in CGEN should be approached with careful attention to the trial outcomes. A successful presentation at SITC could serve as a catalyst for a price rally, whereas any setbacks might lead to a downward revision in stock performance.

In summary, as Compugen prepares to present at SITC, investors should closely monitor the results of COM503 while recognizing the broader implications these results may have on the company's pipeline and future market positioning. Diversification and a strategic timeline for entry or exit based on clinical results are key recommendations in navigating this investment.